A Drug Development Tool for Trial Enrichment in Patients With Autosomal Dominant Polycystic Kidney Disease

Kidney International Reports

Volumn 2, Issue 3, 2017, Pages 451-460

  Perrone, Ronald D ^a   Mouksassi, Mohamad Samer ^b   Romero, Klaus ^c   Czerwiec, Frank S ^d   Chapman, Arlene B ^e   Gitomer, Berenice Y ^f   Torres, Vicente E ^g   Miskulin, Dana C ^a   Broadbent, Steve ^c   Marier, Jean F ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b Pharsight   (Canada)

^c CRITICAL PATH INSTITUTE   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g Mayo Clinic   (United States)

Author keywords

end stage renal disease; renal function decline; total kidney volume; trial enrichment

Indexed keywords

EID: 85024852781     PISSN: 24680249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ekir.2017.02.011     Document Type: Article

References (24)

1. Torres, V.E., Harris, P.C., Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities. J Intern Med 261 (2007), 17–31.
2. Wilson, P.D., Polycystic kidney disease. N Engl J Med 350 (2004), 151–164.
3. Chapman, A.B., Bost, J.E., Torres, V.E., et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 7 (2012), 479–486.
4. Irazabal, M.V., Rangel, L.J., Bergstralh, E.J., et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 26 (2015), 160–172.
5. Grantham, J.J., Cook, L.T., Torres, V.E., et al. Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int 73 (2008), 108–116.
6. Perrone, R.D., Neville, J., Chapman, A.B., et al. Therapeutic area data standards for autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis 66 (2015), 583–590.
7. Tsiatis, A.A., Davidian, M., Joint modeling of longitudinal and time-to-event data: an overview. Statistica Sinica 14 (2004), 809–834.
8. Sweeting, M.J., Thompson, S.G., Joint modelling of longitudinal and time-to-event data with application to predicting abdominal aortic aneurysm growth and rupture. Biom J 53 (2011), 750–763.
9. Cai, T., Pepe, M.S., Zheng, Y., et al. The sensitivity and specificity of markers for event times. Biostatistics 7 (2006), 182–197.
10. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:Suppl 1 (2002), S1–S266.
11. Miller, W.G., Estimating glomerular filtration rate. Clin Chem Lab Med 47 (2009), 1017–1019.
12. Coresh, J., Turin, T.C., Matsushita, K., et al., CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311 (2014), 2518–2531.
13. Chang, W.X., Asakawa, S., Toyoki, D., et al. Predictors and the subsequent risk of end-stage renal disease—usefulness of 30% decline in estimated GFR over 2 years. PLoS One, 10, 2015 e0132927.
14. Breiman, L., Spector, P., Submodel selection and evaluation in regression. The X-random case. Int Stat Rev 60 (1992), 291–319.
15. Schrier, R.W., Abebe, K.Z., Perrone, R.D., et al., for the HALT-PKD Trial Investigators. Blood pressure in early autosomal dominant polycystic kidney disease. New Engl J Med 371 (2014), 2255–2266.
16. Serra, A.L., Poster, D., Kistler, A.D., et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N Engl J Med 363 (2010), 820–829.
17. Food and Drug Administration. Qualification Process for Drug Development Tools, 2014. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm230597.pdf. Accessed December 30, 2016.
18. European Medicines Agency. Qualification of novel methodologies for drug development: guidance to applicants, 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004201.pdf. Accessed December 30, 2016.
19. O'Neill, W.C., Robbin, M.L., Bae, K.T., et al. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis 46 (2005), 1058–1064.
20. Perrone, R.D., Mouksassi, M.-S., Romero, K., et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int. Rep 2 (2017), 442–450.
21. Ku, E., Xie, D., Shlipak, M., et al., CRIC Study Investigators. Change in measured GFR versus eGFR and CKD outcomes. J Am Soc Nephrol 27 (2016), 2196–2204.
22. Food and Drug Administration. Biomarker Qualification Program. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284076.htm. Accessed December 30, 2016.
23. Guidance for Industry. Qualification of Biomarker —Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM458483.pdf. Accessed December 30, 2016.
24. Romero, K., de Mars, M., Frank, D., et al. The coalition against major diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin Pharmacol Ther 86 (2009), 365–367.